These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 38698468)
1. CXCR6-positive circulating mucosal-associated invariant T cells can identify patients with non-small cell lung cancer responding to anti-PD-1 immunotherapy. Qu J; Wu B; Chen L; Wen Z; Fang L; Zheng J; Shen Q; Heng J; Zhou J; Zhou J J Exp Clin Cancer Res; 2024 May; 43(1):134. PubMed ID: 38698468 [TBL] [Abstract][Full Text] [Related]
2. Identification of gene signatures relevant to the efficacy of immune checkpoint inhibitors in non-small cell lung cancer. Liu M; Li Q; Meng X; Cui Y; Sun W; Wang H; Gao Q Medicine (Baltimore); 2024 Dec; 103(49):e40569. PubMed ID: 39654181 [TBL] [Abstract][Full Text] [Related]
3. Differential predictive value of resident memory CD8 Paolini L; Tran T; Corgnac S; Villemin JP; Wislez M; Arrondeau J; Johannes L; Ulmer J; Vieillard LV; Pineau J; Gey A; Quiniou V; Barennes P; Pham HP; Gruel N; Hasan M; Libri V; Mella S; De Percin S; Boudou-Rouquette P; Caidi A; Cremer I; Blons H; Leroy K; Laurent-Puig P; De Saint Basile H; Gibault L; Ravel P; Mami-Chouaib F; Goldwasser F; Fabre E; Damotte D; Tartour E J Immunother Cancer; 2024 Dec; 12(12):. PubMed ID: 39631852 [TBL] [Abstract][Full Text] [Related]
4. Checkpoint based immunotherapy in non-small cell lung cancer: a real-world retrospective study. Liguori L; Giorgio G; Polcaro G; Pagliara V; Malandrino D; Perri F; Cascella M; Ottaiano A; Conti V; Servetto A; Bianco R; Pepe S; Sabbatino F Front Immunol; 2024; 15():1419544. PubMed ID: 39664396 [TBL] [Abstract][Full Text] [Related]
5. Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis. Yang Y; Chen W; Dong L; Duan L; Gao P Clin Transl Oncol; 2024 Oct; 26(10):2488-2502. PubMed ID: 38625495 [TBL] [Abstract][Full Text] [Related]
6. Defining the optimum strategy for identifying adults and children with coeliac disease: systematic review and economic modelling. Elwenspoek MM; Thom H; Sheppard AL; Keeney E; O'Donnell R; Jackson J; Roadevin C; Dawson S; Lane D; Stubbs J; Everitt H; Watson JC; Hay AD; Gillett P; Robins G; Jones HE; Mallett S; Whiting PF Health Technol Assess; 2022 Oct; 26(44):1-310. PubMed ID: 36321689 [TBL] [Abstract][Full Text] [Related]
7. Deep learning analysis of histopathological images predicts immunotherapy prognosis and reveals tumour microenvironment features in non-small cell lung cancer. Wang Y; Ju X; Hua R; Chen J; Dai X; Liu L; Wang G; Bai Y; Hu H; Li X Br J Cancer; 2024 Dec; 131(11):1833-1845. PubMed ID: 39455880 [TBL] [Abstract][Full Text] [Related]
8. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone. Lee CC; Chen CW; Yen HK; Lin YP; Lai CY; Wang JL; Groot OQ; Janssen SJ; Schwab JH; Hsu FM; Lin WH Clin Orthop Relat Res; 2024 Dec; 482(12):2193-2208. PubMed ID: 39051924 [TBL] [Abstract][Full Text] [Related]
9. Icariin promoted ferroptosis by activating mitochondrial dysfunction to inhibit colorectal cancer and synergistically enhanced the efficacy of PD-1 inhibitors. Haoyue W; Kexiang S; Shan TW; Jiamin G; Luyun Y; Junkai W; Wanli D Phytomedicine; 2024 Nov; 136():156224. PubMed ID: 39642461 [TBL] [Abstract][Full Text] [Related]
10. The effector function of mucosal associated invariant T cells alters with aging and is regulated by RORγt. Yang Z; Luo B; Li M; He Z; Ren C; Chen X; Kang X; Chen H; Xu E; Guan W; Xia X Front Immunol; 2024; 15():1504806. PubMed ID: 39669566 [TBL] [Abstract][Full Text] [Related]
11. Liposomal honokiol inhibits non-small cell lung cancer progression and enhances PD-1 blockade via suppressing M2 macrophages polarization. Cheng Y; Han X; Lai X; Wei X Phytomedicine; 2024 Dec; 135():156093. PubMed ID: 39531934 [TBL] [Abstract][Full Text] [Related]
12. Prognostic Significance of PD-L1 Expression on Circulating Myeloid-Derived Suppressor Cells in NSCLC Patients Treated with Anti-PD-1/PD-L1 Checkpoint Inhibitors. Salvia R; Rico LG; Morán T; Bradford JA; Ward MD; Drozdowskyj A; Climent-Martí J; Martínez-Cáceres EM; Rosell R; Petriz J Int J Mol Sci; 2024 Nov; 25(22):. PubMed ID: 39596334 [TBL] [Abstract][Full Text] [Related]
13. Targeting NTRK1 Enhances Immune Checkpoint Inhibitor Efficacy in NTRK1 Wild-Type Non-Small Cell Lung Cancer. Smith MR; Dixon CB; Wang Y; Liu Y; D'Agostino R; Ruiz J; Oliver G; Miller LD; Topaloglu U; Chan MD; Farris M; Su J; Mileham KF; Zhao D; Li W; Sexton T; Lycan T; Haas KM; Grayson JM; Xing F Cancer Res; 2024 Dec; 84(23):4002-4016. PubMed ID: 39250241 [TBL] [Abstract][Full Text] [Related]
14. Euphorbia Pekinensis Rupr. sensitizes colorectal cancer to PD-1 blockade by remodeling the tumor microenvironment and enhancing peripheral immunity. Chen YY; Zeng XT; Gong ZC; Zhang MM; Wang KQ; Tang YP; Huang ZH Phytomedicine; 2024 Dec; 135():156107. PubMed ID: 39368338 [TBL] [Abstract][Full Text] [Related]
15. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery. Bryant A; Hiu S; Kunonga PT; Gajjar K; Craig D; Vale L; Winter-Roach BA; Elattar A; Naik R Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015048. PubMed ID: 36161421 [TBL] [Abstract][Full Text] [Related]
16. Effective treatment strategies and key factors influencing therapeutic efficacy in advanced SMARCA4-deficient non-small cell lung cancer. Liu H; Hong Q; Zheng S; Zhang M; Cai L Lung Cancer; 2024 Dec; 198():108022. PubMed ID: 39541774 [TBL] [Abstract][Full Text] [Related]
17. Prognostic value of immunotherapy in advanced NSCLC based on baseline and dynamic changes in HALP. Su H; Yu C; Sun G; Wang B; Gao Y; Liu X; Song Q; Ma X Biomol Biomed; 2024 Dec; 25(1):29-41. PubMed ID: 39036926 [TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibody targeting CEACAM1 enhanced the response to anti-PD1 immunotherapy in non-small cell lung cancer. Zhao L; Li T; Zhou Y; Wang P; Luo L Int Immunopharmacol; 2024 Dec; 143(Pt 2):113395. PubMed ID: 39426236 [TBL] [Abstract][Full Text] [Related]
19. Mutation-guided chemotherapy-free strategy in first-line immunotherapy for low PD-L1-expressing non-squamous NSCLC. Li H; Liu J; Zhang L; Xu Y; Wang X; Lan S; Cui P; Wang G; Cai S; Cheng Y J Immunother Cancer; 2024 Nov; 12(11):. PubMed ID: 39615893 [TBL] [Abstract][Full Text] [Related]